lifestyle.capitolhilltimes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Thryv Therapeutics Inc.
Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268
April 22, 2026
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
January 14, 2026
Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants
December 17, 2025
Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer
December 2, 2025
Amy Rudolph, PhD, Joins Thryv Therapeutics’ Board of Directors to Support Portfolio Progression into Heart Failure
November 21, 2025
Thryv Therapeutics to Present at the 2025 American Heart Association Scientific Sessions in New Orleans, LA
November 8, 2025
Thryv Therapeutics to Participate in Upcoming 2025 Healthcare Investor Conferences
November 5, 2025